PriceTracker GLP-1
Loading the index…

Try

Find the cheapest for me

What happened

CagriSema is Novo Nordisk's once-weekly injection that pairs semaglutide (the ingredient in Wegovy) with cagrilintide, a long-acting amylin analogue. Novo filed it with the FDA on December 18, 2025 for adults with obesity, or overweight with at least one weight-related condition.

In its third-quarter report on November 4, 2026, Novo listed the US decision for CagriSema in Q4 2026 and said it is "preparing for the US launch of CagriSema in early 2027, subject to regulatory approval." Novo has not published a PDUFA date. As of November 20, 2026 we found no FDA decision in Novo's filings or announcements.

The filing rests on two trials. In REDEFINE 1 (3,417 adults, 68 weeks), people on CagriSema lost an average of 22.7% of their body weight if everyone stayed on treatment, against 2.3% on placebo. Counting everyone who started, including people who stopped, the figure was 20.4% against 3.0%. Stopping because of side effects happened in 5.9% on CagriSema and 3.5% on placebo. Stomach and gut side effects were the most common: nausea in 55% against 12.6%.

What this means for cost

CagriSema has no price yet: Novo has not announced one, and it cannot be sold until the FDA approves it. If you want to start now, these are today's prices for the closest options, from the dated reads on our board and the makers' own self-pay pages.

Compounded drugs are not FDA-approved. Products sold online as "compounded CagriSema" are not the drug in Novo's trials.

What happens next

  • Q4 2026 (by Dec 31, 2026)FDA decision expected, per Novo. We will update this page the day it is announced.
  • Early 2027Novo's planned US launch, if the FDA approves it.
  • H1 2027REDEFINE 11 phase 3 results, per Novo's milestone table.

Sources

  1. Novo Nordisk, financial report for the first nine months of 2026 (Form 6-K, Nov 4, 2026), read 20 Nov 2026
  2. Novo Nordisk, "Novo Nordisk files for FDA approval of CagriSema" (Dec 18, 2025), read 20 Nov 2026
  3. Novo Nordisk, company announcement on REIMAGINE 2 (Form 6-K, Feb 2, 2026), read 20 Nov 2026

Read next